Phase 2a trial evaluates the safety and efficacy of empasiprubart as an add-on therapy in adults with generalized myasthenia gravis, indicating a potential new treatment option.
To present the design of a Phase 2a, proof-of-concept study evaluating safety, efficacy, and tolerability of empasiprubart add-on therapy in participants with generalized myasthenia gravis (gMG) who partially respond to efgartigimod. This is the first of multiple gMG regimens being assessed within a platform study.
No takes yet. Share an insight, caveat, or question.
Guptill et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: